OBJECTIVES: The World Health Organisation has defined Syndrome X as a pathological state that is distinguished by the presence of abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. Individuals diagnosed with metabolic syndrome exhibit a significantly elevated risk, ranging from two to six times greater, of developing cardiovascular disease and type-2 diabetes in comparison to those who do not present with this condition. The rising incidence of metabolic syndrome has prompted research to primarily focus on evaluating the most appropriate treatment regimen. METHOD: This study is a prospective, observational analysis of 48 patients with metabolic syndrome who were admitted to a government-run tertiary care hospital. The study collected and analysed information on patient demographics, comorbidities, supportive laboratory and diagnostic parameters, and hospitalisation treatment regimen. Using version 23 of the SPSS software, the correlation between these factors and treatment duration was examined. RESULTS: Majority of the patients about 43.75 % of patients fell under the 41-55 age category. There were 50% of the patients receiving metformin and 50% receiving metformin with SGLT-2 inhibitors in which the gender distribution showed higher incidence in females of 56.25% than in males of 43.75% .BMI, FBS, PPBS, HbA1C Blood pressure, TSH, h(CRP), HDL, LDL,TG were each of the variables statistically significant at the 5% level of significance with a 95% confidence interval of 0. CONCLUSION: Currently available data highlight the various levels of interaction between metabolic parameters on the clinical efficacy of metformin monotherapy and SGLT-2 inhibitors with metformin add on therapy